Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris
- 29 October 2024
- journal article
- research article
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (11) , 2954-2969
Abstract
Antifungal drug resistance represents a serious global health threat, necessitating new treatment strategies. Here we investigated collateral sensitivity (CS), in which resistance to one drug increases sensitivity to another, and cross-resistance (XR), in which one drug resistance mechanism reduces susceptibility to multiple drugs, since CS and XR dynamics can guide treatment design to impede resistance development, but have not been systematically explored in pathogenic fungi. We used experimental evolution and mathematical modelling of Candida auris population dynamics during cyclic and combined drug exposures and found that especially CS-based drug cycling can effectively prevent the emergence of drug resistance. In addition, we found that a CS-based treatment switch can actively select against or eradicate resistant sub-populations, highlighting the potential to consider CS in therapeutic decision-making upon resistance detection. Furthermore, we show that some CS trends are robust among different strains and resistance mechanisms. Overall, these findings provide a promising direction for improved antifungal treatment approaches.Keywords
All Related Versions
This publication has 114 references indexed in Scilit:
- Cryptococcosis2023
- Collateral sensitivity: An evolutionary trade‐off between antibiotic resistance mechanisms, attractive for dealing with drug‐resistance crisisHealth Science Reports, 2023
- PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida aurisCPT: Pharmacometrics & Systems Pharmacology, 2023
- Scheduling collateral sensitivity‐based cycling therapies toward eradication of drug‐resistant infectionsInternational Journal of Robust and Nonlinear Control, 2022
- Resistance of Candida to azoles and echinocandins worldwideClinical Microbiology and Infection, 2019
- Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patientsInfection, 2017
- Exploring the In Vitro Resistance of Candida parapsilosis to EchinocandinsMycopathologia, 2016
- Fitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug CombinationsCell Reports, 2015
- Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulenceJournal of Microbiology, 2013
- A positive selection for mutants lacking orotidine-5′-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistanceMolecular Genetics and Genomics, 1984